Targets › POLD4
10 programs from 10 companies in 43 trials: 28 Phase 2, 13 Phase 1, 2 Phase 3; Oncology, Neurology, Hematology; next expected readout Dec 2026.
As a component of the tetrameric DNA polymerase delta complex (Pol-delta4), plays a role in high fidelity genome replication and repair. Within this complex, increases the rate of DNA synthesis and decreases fidelity by regulating POLD1 polymerase and proofreading 3' to 5' exonuclease activity. (UniProt, Q9HCU8)
Open in Phaseline: the race on POLD4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangsu Healthy Life Innovation Medical Technology | Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 3 | Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor … | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | AML | Dec 2026 |
| Dana-Farber Cancer Institute | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis | Dec 2026 |
| M.D. Anderson Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Recurrent Acute Lymphoblastic Leukemia | Aug 2027 |
| City of Hope Medical Center | clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Adult Acute Lymphoblastic Leukemia in Remission | Aug 2027 |
| West China Second University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis (LCH) | Jun 2028 |
| Nantes University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Acute Myeloid Leukemia in Remission | Sep 2028 |
| Princess Maxima Center for Pediatric Oncology | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Relapsed Pediatric AML | Dec 2026 |
| Ekaterina Laukhtina | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Advanced Urothelial Carcinoma | Nov 2028 |
| Beijing Immunochina Medical Science & Technology | Fludarabine Phosphate (IM19) Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia … | Jun 2035 |
Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) NHL (1) B-cell Acute Lymphoblastic Leukemia (1) Myelodysplastic Syndromes (1) Refractory Idiopathic Aplastic Anemia (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1)
small molecule (6), mixed (2), other (1), protein or peptide (1)
M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) Princess Maxima Center for Pediatric Oncology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.